It’s also important to note that in the haloperidol-pramipexole study, pramipexole actually improved positive symptoms of some people:
“Pramipexole, a presynaptic dopamine D2/D3 autoreceptor agonist, has been given to haloperidol-treated patients with schizophrenia (n = 15) in an effort to ameliorate residual positive and negative symptoms that have not been satisfactorily influenced by haloperidol alone. Total scores of the positive and negative symptom scale (PANSS) decreased by more than 20% in 9 of 15 patients (reduction of total score: 22-62%)”
You can look at the picture of the results/table of the PANSS score in the original study that I posted in my original pramipexole post, in it you clearly see that positive symptoms scores improved for some people, while for a minority, it did worsen them:
-Pramipexole (Mirapex) for anhedonia and negative symptoms?